Table 3. Univariate and multivariate analyses of relationships between postoperative recurrence and clinicopathological features of 129 stage III CRC patients.

Variable	Without Recurrence (N = 81) / N (%)	With Recurrence (N = 48) / N (%)	Univariate Analysis Unadjusted OR (95% CI)	p-value	Multivariate Analysis Adjusted OR (95%CI)	p-value
Sex, male	50 (61.7)	31 (64.6)	Reference		Reference
female	31 (38.3)	17 (35.4)	0.884 (0.421–1.858)	0.746	0.973 (0.432–2.194)	0.948
Age <65 years	47 (58.0)	26 (54.2)	Reference		Reference
≧65 years	34 (42.0)	22 (45.8)	1.170 (0.570–2.401)	0.669	0.997 (0.456–2.183)	0.994
Tumor size < 5cm	52 (64.2)	29 (60.4)	Reference		Reference
≧5cm	29 (35.8)	19 (39.6)	1.175 (0.563–2.451)	0.668	1.016 (0.433–2.384)	0.970
Histology a
WD +MD	72 (64.9)	39 (81.3)	Reference		Reference
PD	9 (11.1)	9 (18.8)	1.846 (0.677–5.032)	0.226	1.758 (0.552–5.596)	0.340
T stage
T1+T2	12 (14.8)	4 (8.3)	Reference		Reference
T3+T4	69 (85.2)	44 (91.7)	1.913 (0.580–6.308)	0.280	1.556 (0.411–5.895)	0.515
N stage
N1	54 (66.7)	33 (63.8)	Reference		Reference
N2	27 (33.3)	15 (31.3)	0.909 (0.423–1.955)	0.807	0.869 (0.362–2.086)	0.754
Perineural invasion
No	50 (61.7)	36 (75.0)	Reference		Reference
Yes	31 (72.1)	12 (25.0)	0.538 (0.243–1.187)	0.122	0.503 (0.205–1.234)	0.134
Vascular invasion
No	52 (64.2)	31 (64.6)	Reference		Reference
Yes	29 (35.8)	17 (35.4)	0.983 (0.466–2.073)	0.965	1.024 (0.451–2.321)	0.955
Tumor location b
Right	25 (30.9)	15 (31.3)	Reference		Reference
Left	56 (69.1)	33 (63.8)	0.982 (0.454–2.124)	0.963	1.047 (0.437–2.512)	0.918
Methylation level
High	18 (22.2)	1 (2.1)	Reference		Reference
Low	63 (77.8)	47 (97.9)	13.429 (1.731–104.187)	0.002	14.107 (1.776–112.089)	0.012

Each risk factor was adjusted for all other risk factors listed in the table.

^aWD, well-differentiated; MD, moderately differentiated; PD, poorly differentiated.

^bTumor location is divided according to sites to the right or left of the splenic flexure.